Dr Rupert Osborn has worked in the field of technology commercialisation since 1996. His specific areas of expertise are transaction support (particularly licensing strategy and negotiation) and innovation management and strategy. He helps organisations embrace open innovation through strategic intellectual property advice, training and hands-on deal making support. His experience covers the commercialisation of different forms of intellectual property including trademark, copyright and patent licensing. He has particular expertise in the Agricultural Biotechnology sector having gained industry experience with Zeneca Agrochemicals (now Syngenta) prior to founding IP Pragmatics. Rupert has an MA from Cambridge University and a PhD from Warwick University.

Dr Claude Kaplan has over 14 years´ experience in commercialising technologies from multinationals, SMEs, government research institutes and universities across UK, EU, US, Japan and New Zealand. His specific focus in on the commercialisation of technologies in Animal Health, In-Vitro Diagnostics and Life Science Research. He has successfully launched and run 2 spin-outs from UK institutes; one in animal diagnostics and one in infectious disease diagnostics. He holds a MA & PhD from University of Cambridge, professional qualifications in law, human resources & marketing and gained his industrial experience with Unilever and TTP.

Following over six years of managing late-stage global clinical trials with big pharma, Ronnie Georghiou joined IP Pragmatics in 2007. To date he has led two long-term commercialisation projects within public research institutes, provided business development and competitive intelligence support to a number of SMEs and been directly involved with securing >£3M (public and private funding) for client commercialisation opportunities.

More recently in Oct 2010, Ronnie successfully established the Australia & New Zealand office in Sydney. His specific focus is on commercialising products and services spanning anti-infectives, pharmaceuticals, IVD diagnostics and Fast Moving Consumer Goods markets. He holds a BSc (Hons) in Medical Biochemistry from University of London and an MBA from Imperial College.

Adam joined IP Pragmatics in 2005 as a director. He started his career in sales and marketing with one of the USA's largest telecommunications companies rising to a national and key accounts position selling consultative services to Fortune 100 companies. Returning to the UK in 2000, he entered the Intellectual Property profession and worked for two private practice patent attorney firms in business development roles. At IP Pragmatics, he has overseen the redevelopment of NetsPat the ASP software IP cost forecasting tool into IP Forecaster and the growth in IP Pragmatics other service activities. In 2011 Adam took up the position of CEO for our newly formed joint venture company, Patrafee UK. Adam holds a BA from University College London.

John is an experienced entrepreneur who has built and sold a number of businesses. He originally trained and worked as a teacher before founding the Cromer Crab Company in 1980. John successfully built the company and sold it to Perkins Foods Plc in 1993, before partaking in a management buy-out of Perkin's seafood division in 1995, to form the Seafood Company. He remained with the Seafood Company until 2000 having been responsible for chilled production and supply to UK supermarkets including the building of a new £4.5m production facility in Cromer, employing 200 people. In 2001 he co-founded the patent and trademark company, ip21, building it into a thriving patent practice. In 2009 he sold his shareholding in ip21. John now applies his considerable commercial experience to help a number of growing businesses as a non-executive director, including a specialised electronics, telecoms and computing patent and trademark firm based in London.

Win holds a degree in chemistry from Birmingham University and a doctorate from Cambridge. She initially trained as a patent attorney in private practice, and went on to work in industry with time spent at Shell. The British Technology Group (BTG) and as Head of Patents for Burmah Castrol. On leaving Burmah, Win developed an online patents management system and founded NetsPat Limited (now IP Forecaster) a business that she has successfully built up over the last nine years. Win has over 30 years experience many different aspects of Intellectual Property.

Elaine Eggington has over 12 years´ experience in commercialising early stage technologies through venture capital investment and consultancy. She was the Investment Manager with day to day responsibility for the Lachesis Fund, the £8m University Challenge Fund for the East Midlands, managing a portfolio of 30 start-up companies and development technologies. Her areas of specialisation include Instrumentation, Vaccines and Fundraising Support. Previously, she spent 12 years as an information manager in the life sciences industry, working in the NHS, at Peptide Therapeutics and Schering Agrochemicals. She has an MA from the University of Cambridge and an MSc from The City University.

Sophie Brayne completed her degree in Biological Sciences with Pharmacology Honours at the University of Edinburgh in 2011. Prior to joining IP Pragmatics, she worked with science policy at the Society of Biology and in the marketing division of Pfizer Animal Health in New York. Her role involves coordinating our marketing efforts and includes responsibility for the UK marketing of IPRIS, our unique patent renewals partner for University and small and medium-sized clients.

Dr Rupert Osborn has worked in the field of technology commercialisation since 1996. His specific areas of expertise are transaction support (particularly licensing strategy and negotiation) and innovation management and strategy. He helps organisations embrace open innovation through strategic intellectual property advice, training and hands-on deal making support. His experience covers the commercialisation of different forms of intellectual property including trademark, copyright and patent licensing. He has particular expertise in the Agricultural Biotechnology sector having gained industry experience with Zeneca Agrochemicals (now Syngenta) prior to founding IP Pragmatics. Rupert has an MA from Cambridge University and a PhD from Warwick University.

Dr Claude Kaplan has over 14 years' experience in commercialising technologies from multinationals, SMEs, government research institutes and universities across UK, EU, US, Japan and New Zealand. His specific focus in on the commercialisation of technologies in Animal Health, In-Vitro Diagnostics and Life Science Research. He has successfully launched and run 2 spin-outs from UK institutes; one in animal diagnostics and one in infectious disease diagnostics. He holds a MA & PhD from University of Cambridge, professional qualifications in law, human resources & marketing and gained his industrial experience with Unilever and TTP.

Following over six years of managing late-stage global clinical trials with big pharma, Ronnie Georghiou joined IP Pragmatics in 2007. To date he has led two long-term commercialisation projects within public research institutes, provided business development and competitive intelligence support to a number of SMEs and been directly involved with securing >£3M (public and private funding) for client commercialisation opportunities.
More recently in Oct 2010, Ronnie successfully established the Australia & New Zealand office in Sydney. His specific focus is on commercialising products and services spanning anti-infectives, pharmaceuticals, IVD diagnostics and Fast Moving Consumer Goods markets. He holds a BSc (Hons) in Medical Biochemistry from University of London and an MBA from Imperial College.

Dr Quinton Fivelman is a life science business development manager and has a range of business consultancy and development experience in European and developing world markets. He previously managed business development and knowledge transfer at the London School of Hygiene and Tropical Medicine (University of London) where he was responsible for managing proof of concept funding for a range of public health technologies and launching new business initiatives by assisting many projects to move from the laboratory to the marketplace. He has a PhD in malaria molecular genetics and drug combinations from the London School of Hygiene and Tropical Medicine and an Honours degree in Pharmacology, Chemistry and Microbiology from the University of Cape Town, South Africa.

Rufus Charles has been working on the exploitation of life science IP for the last 14 years. Prior to joining IPPL he led the new ventures arm of a technology transfer company where he was instrumental in founding the £4M Iceni Seedcorn Fund and served on its investment board. He also established operations for and served on the board of a large bioincubator facility. Additionally, Rufus has experience in life science licensing, food & agri business and consulting in the UK and overseas. Rufus has an MSc from Imperial College and an MBA from INSEAD.